Fury Matthew G - Oncology Clinical Sciences, Regeneron Pharmaceuticals

基本信息

浏览量：23

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 12 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 2/3 Study of Fianlimab, Cemiplimab, Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Nashat Gabrail,Miranda Gogishvili,Tamta Makharadze, Nino Chikhladze, Nicole Faulkner,Santosh Nair,Emad Ibrahim, Daniel Brungs, Luke Dreisbach, Gopal Kunta,Solange Peters, Christopher Nguyen, Majed Ghattas,Siyu Li,Mark Salvati,Israel Lowy,Matthew G. Fury, Luca Paoluzzi,Tamar Melkadze

Journal of clinical oncologyno. 16_suppl (2024): TPS8660-TPS8660

引用0浏览0引用

A Phase 3 Trial of Fixed Dose Combinations of Fianlimab (Anti–lag-3) + Cemiplimab (Anti–pd-1) Versus Relatlimab + Nivolumab in Patients with Unresectable or Metastatic Melanoma

Nikhil I. Khushalani,Jayakumar Mani,Jocelyn Booth, Zoe Zhang,Mark Salvati,Israel Lowy,Matthew G. Fury,Karl D. Lewis, Garen Manvelian, Hussein A. Tawbi

Journal of clinical oncologyno. 16_suppl (2024): TPS9611-TPS9611

引用0浏览0引用

Combination of Cemiplimab and ISA101b Vaccine for the Treatment of Recurrent/metastatic HPV16 Cervical Cancer

Domenica Lorusso,Ana Oaknin,Giuliano Santos Borges,Fernanda Damian, Petronella B. Ottevanger,Toon Van Gorp, Carlos Eduardo Paiva,Judith R. Kroep,Yong Man Kim,Hee Seung Kim,Jae Kwan Lee,Cornelis J.M. Melief, Leon Hooftman, Saidatun Najmiah Mohd Jamil, Suk Young Yoo,Frank Seebach,Israel Lowy,Matthew G. Fury,Melissa Mathias, Nicoletta Colombo

Journal of clinical oncologyno. 16_suppl (2024): 5522-5522

引用0浏览0引用

Supplementary Figure S1 from the PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Jacob D. Soumerai,Andrew D. Zelenetz,Craig H. Moskowitz,M. Lia Palomba, Paul A. Hamlin,Ariela Noy,David J. Straus,Alison J. Moskowitz,Anas Younes,Matthew J. Matasar,Steven M. Horwitz,Carol S. Portlock,Jason A. Konner,Mrinal M. Gounder,David M. Hyman,Martin H. Voss,Matthew G. Fury,Devika Gajria,Richard D. Carvajal,Alan L. Ho, Jan H. Beumer,Brian Kiesel, Zhigang Zhang,Alice Chen, Richard F. Little,Christine Jarjies, Thu O. Dang, Fallon France,Nishant Mishra,John F. Gerecitano

crossref（2023）

引用0浏览0引用

Supplementary Data from First-In-Human Study of Cemiplimab Alone or in Combination with Radiotherapy And/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos,Melissa L. Johnson,Albert C. Lockhart, Kathleen Moore,Gerald S. Falchook, Silvia C. Formenti,Aung Naing,Richard D. Carvajal,Lee S. Rosen, Glen J. Weiss,Rom S. Leidner,Jingjin Li,Anne Paccaly,Minjie Feng,Elizabeth Stankevich,Israel Lowy,Matthew G. Fury,Marka R. Crittenden

crossref（2023）

引用0浏览0引用

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti?PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

Victor Moreno, Pilar Garrido,Kyriakos P. Papadopoulos, Maria Jose De Miguel Luken,Marta Gil-Martin,Raid Aljumaily,Lee S. Rosen,Petra Rietschel,Kosalai K. Mohan, Suk-Young Yoo,Elizabeth Stankevich,Israel Lowy,Matthew G. Fury

LUNG CANCER (2021): 151-155

引用0浏览0引用

547 CERPASS: A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab ± RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Andrew Mark Haydon,Nikhil I. Khushalani, Caroline Robert,Daniel Brungs,Frances A. Collichio,A. Dimitrios Colevas, Annette May Ling Lim,Ragini Reiney Kudchadkar,Wanxing Chai-Ho,Gregory A. Daniels,Jose Lutzky,Jenny H. J. Lee,Ann W. Silk,Celeste Lebbe,Jean-Jacques Grob, Margaret Smith,Matthew G. Fury,Muhammad Alamgeer,Andrew Graham Hill,Michael Robert Migden

Regular and Young Investigator Award Abstractsno. Suppl 2 (2021): A577-A577

引用1浏览0引用

OncoTree: A Cancer Classification System for Precision Oncology

Ritika Kundra,Hongxin Zhang,Robert P. Sheridan,S. Joseph Sirintrapun,Avery Wang,Angelica Ochoa,Manda Wilson,Benjamin Groß,Yichao Sun, Ramyasree Madupuri,Baby A. Satravada,Dalicia N. Reales,Efsevia Vakiani,Hikmat Al‐Ahmadie,Ahmet Doğan,Maria E. Arcila,Ahmet Zehir,Steven B. Maron,Michael F. Berger,Cristina Viaplana,Katherine A. Janeway,Matthew D. Ducar,Lynette M. Sholl,Snjezana Doğan,Philippe L. Bédard,Lea F. Surrey, Iker Huerga Sanchez,Aijaz Syed,Anoop Balakrishnan Rema,Debyani Chakravarty,Sarah P. Suehnholz,Moriah H. Nissan,Gopakumar V. Iyer,Rajmohan Murali,Nancy Bouvier,Robert A. Soslow,David M. Hyman,Anas Younes,Andrew M. Intlekofer,James J. Harding,Richard D. Carvajal,Paul Sabbatini,Ghassan K. Abou‐Alfa,Luc G.T. Morris,Yelena Y. Janjigian,Meighan M. Gallagher,Tara A. Soumerai,Ingo K. Mellinghoff,A. Ari Hakimi,Matthew G. Fury,Jason T. Huse,Aditya Bagrodia,Meera Hameed,Stacy B. Thomas,Stuart M. Gardos,Ethan Cerami,Tali Mazor,Priti Kumari,Pichai Raman,Priyanka Shivdasani,Suzanne P. MacFarland,Scott Newman,Angela J. Waanders,Jianjiong Gao,David B. Solit,Nikolaus Schultz

JCO clinical cancer informaticspp.221-230, (2021)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn